- Home
- NXTC vs NRXS Comparison
NXTC vs NRXS Comparison
Compare NXTC & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- NRXS
- Stock Information
- Founded
- NXTC 2015
- NRXS 2011
- Country
- NXTC United States
- NRXS United States
- Employees
- NXTC N/A
- NRXS N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- NRXS
- Sector
- NXTC Health Care
- NRXS
- Exchange
- NXTC Nasdaq
- NRXS Nasdaq
- Market Cap
- NXTC 13.9M
- NRXS 13.0M
- IPO Year
- NXTC 2019
- NRXS 2023
- Fundamental
- Price
- NXTC $0.48
- NRXS $2.49
- Analyst Decision
- NXTC Strong Buy
- NRXS Strong Buy
- Analyst Count
- NXTC 2
- NRXS 1
- Target Price
- NXTC $3.50
- NRXS $7.00
- AVG Volume (30 Days)
- NXTC 336.1K
- NRXS 155.9K
- Earning Date
- NXTC 07-31-2025
- NRXS 08-08-2025
- Dividend Yield
- NXTC N/A
- NRXS N/A
- EPS Growth
- NXTC N/A
- NRXS N/A
- EPS
- NXTC N/A
- NRXS N/A
- Revenue
- NXTC N/A
- NRXS $2,934,945.00
- Revenue This Year
- NXTC N/A
- NRXS $138,883.78
- Revenue Next Year
- NXTC N/A
- NRXS $118.59
- P/E Ratio
- NXTC N/A
- NRXS N/A
- Revenue Growth
- NXTC N/A
- NRXS 27.52
- 52 Week Low
- NXTC $0.22
- NRXS $1.33
- 52 Week High
- NXTC $1.82
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- NXTC 44.82
- NRXS 49.91
- Support Level
- NXTC $0.45
- NRXS $2.33
- Resistance Level
- NXTC $0.51
- NRXS $2.67
- Average True Range (ATR)
- NXTC 0.07
- NRXS 0.17
- MACD
- NXTC -0.01
- NRXS -0.01
- Stochastic Oscillator
- NXTC 3.24
- NRXS 46.43
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).